文献速递生殖医学

健康反应者在体外受精治疗中触发卵母细胞成熟:系统综述与网络Meta分析

Triggering oocyte maturation in in vitro fertilization treatment in healthy responders: a systematic review and network meta-analysis.
PubMed 文献 · Fertil Steril · 2024-11-14

该系统综述与网络Meta分析纳入12项高质量随机对照试验共1931名预测健康反应者,比较hCG、GnRH激动剂、双触发和双重触发四种方案。结果显示双触发在临床妊娠率方面累积排名概率最高(85.1%),但各方案在获卵数、成熟卵母细胞数和流产率上无显著差异。GnRH激动剂相比hCG的卵巢过度刺激综合征发生率数值更低,但置信区间跨1,未达统计学显著。

要点

  • 双触发在临床妊娠率方面累积排名概率最高(85.1%),但与其他方案比较的置信区间多跨1。
  • 活产率方面双触发优于hCG(RR 1.31,95%CI 1.00-1.70)和GnRH激动剂(RR 1.60,95%CI 1.05-2.43),但原文指出证据受可用RCT限制。
  • 获卵数、成熟卵母细胞数和流产率在各触发方案间无显著差异。

核心结论

  • 原文结论指出,没有证据表明使用GnRH激动剂、双触发或双重触发方案在改善临床妊娠率方面优于hCG触发。
  • 活产率可能从双触发中获益,但结果受可用随机对照试验的限制。
  • 需要更大规模的多中心试验来进一步评估活产率和理解长期结局。

研究设计与样本

  • 系统综述与网络Meta分析,检索PubMed、MEDLINE、EMBASE、临床试验注册库和Cochrane系统综述数据库截至2023年12月的随机对照试验。
  • 纳入12项高质量随机对照试验,共1931名女性,比较hCG触发与GnRH激动剂触发、双触发和双重触发。
  • 统计分析使用STATA版本16。

主要发现

  • 临床妊娠率:hCG vs GnRH激动剂触发RR 1.13(95%CI 0.80-1.60),hCG vs 双触发RR 1.23(95%CI 0.92-1.65),hCG vs 双重触发RR 0.38(95%CI 0.21-0.69),GnRH激动剂 vs 双触发RR 1.09(95%CI 0.70-1.70),GnRH激动剂 vs 双重触发RR 0.34(95%CI 0.17-0.67),双重触发 vs 双触发RR 0.31(95%CI 0.16-0.60)。
  • 双触发的累积排名曲线下面积最高(85.1%),提示在临床妊娠率方面疗效最优。
  • 活产率:双触发 vs hCG触发RR 1.31(95%CI 1.00-1.70),双触发 vs GnRH激动剂触发RR 1.60(95%CI 1.05-2.43),原文指出连通性有限。
  • 卵巢过度刺激综合征发生率:GnRH激动剂相比hCG触发RR 0.56(95%CI 0.19-1.75),原文未报告双触发或双重触发的卵巢过度刺激综合征发生率随机对照试验。
  • 获卵数、成熟卵母细胞数和流产率在各触发方案间无显著差异。

关键数值与推荐

  • 临床妊娠率:hCG vs GnRH激动剂触发RR 1.13(95%CI 0.80-1.60),hCG vs 双触发RR 1.23(95%CI 0.92-1.65),hCG vs 双重触发RR 0.38(95%CI 0.21-0.69)。
  • 临床妊娠率:GnRH激动剂 vs 双触发RR 1.09(95%CI 0.70-1.70),GnRH激动剂 vs 双重触发RR 0.34(95%CI 0.17-0.67),双重触发 vs 双触发RR 0.31(95%CI 0.16-0.60)。
  • 活产率:双触发 vs hCG触发RR 1.31(95%CI 1.00-1.70),双触发 vs GnRH激动剂触发RR 1.60(95%CI 1.05-2.43)。
  • 卵巢过度刺激综合征发生率:GnRH激动剂相比hCG触发RR 0.56(95%CI 0.19-1.75)。

临床怎么用

  • 原文结论指出没有证据表明GnRH激动剂、双触发或双重触发方案在改善临床妊娠率方面优于hCG触发。
  • 原文指出活产率可能从双触发中获益,但结果受可用随机对照试验的限制。
  • 原文未据此给出推荐。

局限性

  • 原文指出活产率结果受可用随机对照试验的限制(连通性有限)。
  • 原文指出需要更大规模的多中心试验来进一步评估活产率和理解长期结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare efficacy and safety of human chorionic gonadotropin (hCG), gonadotropin-releasing hormone (GnRH) agonist, dual, and double triggers in predicted healthy responders undergoing ovarian stimulation and in vitro fertilization. DESIGN: A systematic review and network meta-analysis of randomized controlled trials (RCTs). DATA SOURCES: Randomized controlled trials indexed in PubMed, MEDLINE, EMBASE, clinical trial registries, and Cochrane Database of Systematic Reviews up to December 2023. STUDY SELECTION AND SYNTHESIS: Twelve high-integrity RCTs comprising 1,931 women were included, which compared hCG trigger with GnRH agonist trigger, dual trigger, and double trigger. Statistical analysis was performed using STATA version 16. MAIN OUTCOME MEASURES: Key outcomes included clinical pregnancy rates (CPR), live birth rates (LBR), number of oocytes, number of mature oocytes, miscarriage rates, and rates of ovarian hyperstimulation syndrome. RESULTS: The network meta-analysis for CPR were risk ratio (RR), 1.13; (95% confidence interval [CI], 0.80-1.60) for hCG vs. GnRH agonist trigger, RR, 1.23 (95% CI, 0.92-1.65) for hCG vs. dual trigger, RR, 0.38 (95% CI, 0.21-0.69) for hCG vs. double trigger, RR, 1.09 (95% CI, 0.70-1.70) for GnRH agonist vs. dual trigger and 0.34 (95% CI, 0.17-0.67) for GnRH agonist vs. double trigger, and RR, 0.31 (95% CI, 0.16-0.60) for double vs. dual trigger. Dual trigger demonstrated the highest Surface Under the Cumulative Ranking (85.1%), indicating superior efficacy for CPR. For LBR, although connectivity was limited, the RR was 1.31 (95% CI, 1.00-1.70) for dual vs. hCG trigger, and RR, 1.60 (95% CI, 1.05-2.43) for dual vs. GnRH agonist trigger. Ovarian hyperstimulation syndrome rates were significantly lower with the GnRH agonist compared with hCG trigger (RR, 0.56; 95% CI, 0.19-1.75). There were no RCTs reporting ovarian hyperstimulation syndrome rates with the use of dual or double trigger. No significant differences were observed in the number of oocytes retrieved, mature oocytes, or miscarriage rates among the trigger protocols. CONCLUSION AND RELEVANCE: The findings indicate that there is no evidence to suggest that using GnRH agonist, dual, or double protocols is superior to hCG trigger in improving CPR. Although LBR may benefit from dual trigger, results are limited by available RCTs. Larger, multicenter trials are needed for further evaluation of LBR and understanding of long-term outcomes.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Beebeejaun Y, Copeland T, Duffy JMN, et al. Triggering oocyte maturation in in vitro fertilization treatment in healthy responders: a systematic review and network meta-analysis. Fertil Steril. 2024. PMID: 39547644. doi:10.1016/j.fertnstert.2024.11.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。